Action CEL-SCI CORPORATION
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Autres langues CEL-SCI Corporation Nyse

Actions

US1508375086

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Cel-Sci Appoints Robert Watson Board's Chair
CEL-SCI Appoints Robert Watson as Chairperson of the Board
CEL-SCI Corporation Appoints Robert Watson as Chairperson of the Board
CEL-SCI Corporation(NYSEAM:CVM) dropped from Russell Microcap Value Index
CEL-SCI Corporation(NYSEAM:CVM) dropped from Russell 3000E Value Index
CEL-SCI Corporation Presents Head & Neck Cancer Data At Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated with Multikine in the Target Population
CEL-SCI Presents Head and Neck Cancer Data at Iddst Annual Congress in Budapest, Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
CEL-SCI Corporation (von First Berlin Equity Research GmbH...
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor
Cel-Sci: Fiscal Q2 Earnings Snapshot
CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results
CEL-SCI Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head and Neck Cancer
Cel-Sci Gets US FDA Clearance to Proceed With Confirmatory Study for Cancer Drug Multikine
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
CEL-SCI Corporation Announces Significantly Positive Outcome from its Recent Meeting with U.S. Food and Drug Administration Regarding Path to Approval for its First-Line Investigational Cancer Immunotherapy Multikine
CEL-SCI Corporation Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
CEL-SCI Corporation Appoints Mario Gobbo as Board of Directors
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action CVM
  4. Action
  5. Actualités CEL-SCI Corporation
  6. Autres langues